Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIASA 3: Oral Antidiabetics in South Asian Women
NCT04662866Phase 2Unknown
- Sponsor
- Oslo University Hospital
- Start
- Feb 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs), pioglitazone, empagliflozin and linagliptin in impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) (4 arms), sponsored by Oslo University Hospital. Primary endpoint: Endogenous glucose production during fasting at 12 weeks. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)pioglitazoneempagliflozinlinagliptin
03
Conditions
impaired glucose tolerance (IGT)impaired fasting glucose (IFG)
Beyond the preview
Go deeper on NCT04662866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662866.